Sientra, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Ronald Menezes
- Full Time Employees
- 304
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 420 South Fairview Avenue Santa Barbara CA United States of America 93117
- IPO Date
- Oct 29, 2014
- CIK
- 0001551693
- Website
- sientra.com
- Similar Companies
- Business
- Sientra, Inc. is a medical aesthetics company primarily engaged in the development, manufacturing, and commercialization of breast implants and related products used in breast augmentation and reconstruction surgeries. The company's product portfolio includes FDA-approved fifth-generation round and shaped silicone gel breast implants; the AlloX2® and AlloX2Pro™ breast tissue expanders featuring patented dual-port and integral drain technology; the Viality™ fat transfer system enhanced with AuraClens™ for high viability fat transfer; the SimpliDerm human acellular dermal matrix for reconstructive procedures; and BIOCORNEUM®, a leading scar management silicone gel product. Founded in 2007 and headquartered in Santa Barbara, California, Sientra markets its products primarily to board-certified plastic surgeons and operates within the United States. In recent major developments, Sientra filed for Chapter 11 bankruptcy protection in February 2024 and has since pursued the sale of key business assets. In April 2024, Tiger Aesthetics Medical, LLC acquired substantially all assets related to Sientra’s breast implant and tissue expander business, including the manufacturing facilities in Franklin, Wisconsin, and assumed certain liabilities and customer warranties. Concurrently, Nuance Intermediary, LLC acquired the assets of Sientra's BIOCORNEUM scar management business in an $8 million cash transaction. Under the new ownership of Tiger Aesthetics, a company specializing in regenerative medicine and aesthetic products, the Sientra brand continues to offer its established portfolio while planning to expand into innovative regenerative aesthetic therapies, leveraging Sientra's market presence and advanced technologies. These strategic asset sales signify a major operational and ownership restructure aimed at financial stability and long-term growth within the aesthetics market segment. Tiger Aesthetics has committed to maintaining existing manufacturing and operational standards as part of the integration process. Sientra’s offerings now align with regenerative medicine initiatives and aesthetic device innovation under the Tiger Aesthetics umbrella. These changes mark a significant shift from the company's prior independent operations to being a division within a broader regenerative medical aesthetics platform.
Sienna Resources Inc. Announces a Flow-Through Private Placement
Sienna Resources Inc. Closes First Tranche of Private Placement to Fund Multiple Work Programs
Sienna Resources Inc. Announces Private Placement to Fund Multiple Work Programs
Sienna Resources Inc. Closes Private Placement
Sienna Resources Inc. Announces Private Placement
Sientra Announces Completion and Winning Bidders of its Section 363 Sales Auction
Sientra to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process
Sientra, Inc. (SIEN) Q3 2023 Earnings Call Transcript
Sientra Reports Third Quarter Financial and Operational Results
Sientra to Present at the Stifel 2023 Healthcare Conference
Sientra Reports Preliminary Unaudited Third Quarter 2023 Financial Results and Provides Update on Outlook
The 7 Best Short-Squeeze Stocks to Buy Now: September 2023
Sientra (SIEN) Reports Q2 Loss, Lags Revenue Estimates
Sientra Reports Record Second Quarter Financial and Operational Results
Sientra to Report Second Quarter 2023 Financial Results on August 10, 2023
As Sientra Options Become Less Bullish This Week, Short Sellers Are Moving In
Sientra stock rockets to pace premarket gainers after FDA clearance of tissue expander
Why Fast-paced Mover Sientra (SIEN) Is a Great Choice for Value Investors
Despite Fast-paced Momentum, Sientra (SIEN) Is Still a Bargain Stock
Sientra, Inc. (SIEN) Q1 2023 Earnings Call Transcript